Brokerages Expect Assembly Biosciences Inc (ASMB) to Post ($0.79) Earnings Per Share

Shares of Assembly Biosciences Inc (NASDAQ:ASMB) have been given an average broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.

Brokers have set a 12-month consensus target price of $42.50 for the company and are predicting that the company will post ($0.79) EPS for the current quarter, according to Zacks. Zacks has also given Assembly Biosciences an industry rank of 236 out of 265 based on the ratings given to related companies.

A number of research firms have weighed in on ASMB. BidaskClub upgraded Assembly Biosciences from a “hold” rating to a “buy” rating in a research note on Friday, August 18th. ValuEngine downgraded Assembly Biosciences from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. Zacks Investment Research upgraded Assembly Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th. Chardan Capital restated a “buy” rating on shares of Assembly Biosciences in a research note on Sunday, September 17th. Finally, Jefferies Group assumed coverage on Assembly Biosciences in a research note on Wednesday, November 8th. They issued a “buy” rating and a $50.00 price target for the company.

Assembly Biosciences (ASMB) traded up $1.78 during mid-day trading on Wednesday, reaching $44.39. The company’s stock had a trading volume of 297,493 shares, compared to its average volume of 185,988. Assembly Biosciences has a 12-month low of $11.07 and a 12-month high of $52.37.

In other news, Director William R. Ringo sold 1,000 shares of Assembly Biosciences stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $29.55, for a total transaction of $29,550.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 3,000 shares of company stock valued at $112,620 over the last quarter. 19.60% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently modified their holdings of ASMB. Vanguard Group Inc. boosted its stake in shares of Assembly Biosciences by 11.2% during the 1st quarter. Vanguard Group Inc. now owns 503,851 shares of the biopharmaceutical company’s stock worth $12,843,000 after acquiring an additional 50,615 shares during the period. Geode Capital Management LLC lifted its holdings in Assembly Biosciences by 32.3% during the 1st quarter. Geode Capital Management LLC now owns 97,964 shares of the biopharmaceutical company’s stock worth $2,497,000 after purchasing an additional 23,926 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in Assembly Biosciences during the 1st quarter worth approximately $242,000. Acadian Asset Management LLC lifted its holdings in Assembly Biosciences by 58.2% during the 2nd quarter. Acadian Asset Management LLC now owns 16,336 shares of the biopharmaceutical company’s stock worth $338,000 after purchasing an additional 6,011 shares during the last quarter. Finally, Strs Ohio acquired a new stake in Assembly Biosciences during the 2nd quarter worth approximately $280,000. Institutional investors own 62.09% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was first posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://stocknewstimes.com/2017/12/16/brokerages-expect-assembly-biosciences-inc-asmb-to-post-0-79-earnings-per-share.html.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply